A strong H1/19E saw +21% organic revenue growth, which was further enhanced by consolidation of the WatBio acquisition. Efficiency and cost savings initiatives at WatBio have been implemented, albeit at a slower pace than initially expected. Despite this delay our FY20E Adj EBITDA (including change in deferred revenue) increases £0.3m (due to IFRS 16 impact) to £6.0m (without the accounting impact it is unchanged).
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Filta Group Holdings Plc - H1/19A Interim Results
- Published:
09 Sep 2019 -
Author:
Peter Renton -
Pages:
7
A strong H1/19E saw +21% organic revenue growth, which was further enhanced by consolidation of the WatBio acquisition. Efficiency and cost savings initiatives at WatBio have been implemented, albeit at a slower pace than initially expected. Despite this delay our FY20E Adj EBITDA (including change in deferred revenue) increases £0.3m (due to IFRS 16 impact) to £6.0m (without the accounting impact it is unchanged).